中危非肌层浸润性膀胱癌多次复发的自然史:一项前瞻性队列研究的启示
基于Be-Well前瞻性队列中291例中危非肌层浸润性膀胱癌患者,中位随访38个月,5年首次复发风险为54.4%。首次复发后2年内60.1%出现第二次复发,第二次复发后3年内51.5%出现第三次复发。复发次数越多,5年进展风险显著升高。
要点
- 中危非肌层浸润性膀胱癌5年首次复发风险为54.4%,多次复发常见。
- 女性、肿瘤较大、既往复发次数多与多次复发相关,维持BCG与复发减少相关。
- 1、2、3次及以上复发患者的5年进展风险分别为9.5%、21.9%、37.9%。
核心结论
- 中危非肌层浸润性膀胱癌多次复发常见,且与进展相关。
- 女性、较大肿瘤、既往复发次数多及未维持BCG与多次复发相关。
- 多次复发可能作为中危非肌层浸润性膀胱癌的临床试验终点。
研究设计与样本
- Be-Well前瞻性队列研究,纳入2015至2019年在Kaiser Permanente Northern California诊断的中危非肌层浸润性膀胱癌患者291例,中位随访38个月。
主要发现
- 291例患者5年首次复发风险为54.4%。
- 首次复发后(n=137),2年内60.1%出现第二次复发。
- 第二次复发后(n=70),3年内51.5%出现第三次复发。
- 多变量分析中,女性(HR 1.51,P< .01)、肿瘤增大(HR 1.14,P< .01)和既往复发次数(HR 1.24,P< .01)与多次复发相关;维持BCG(HR 0.66,P = .03)与复发减少相关。
- 1、2、3次及以上复发患者的5年进展风险分别为9.5%、21.9%、37.9%,差异显著(P< .01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe the risk of multiple recurrences in intermediate-risk non-muscle invasive bladder cancer (IR-NMIBC) and their impact on progression. Prognostic studies of IR-NMIBC have focused on initial recurrences, yet little is known about subsequent recurrences and their impact on progression. MATERIALS AND METHODS: IR-NMIBC patients from the Be-Well Study, a prospective cohort study of NMIBC patients diagnosed from 2015 to 2019 at Kaiser Permanente Northern California, were identified. The frequency of first, second, and third intravesical recurrences of urothelial carcinoma were characterized using conditional Kaplan-Meier analyses and random-effects shared-frailty models. The association of multiple recurrences with progression was examined. RESULTS: In 291 patients with IR-NMIBC (median follow-up 38 months), the 5-year risk of initial recurrence was 54.4%. After initial recurrence (n = 137), 60.1% of patients had a second recurrence by 2 years. After second recurrence (n = 70), 51.5% of patients had a third recurrence by 3 years. In multivariable analysis, female sex (Hazard Ratio 1.51, P< .01), increasing tumor size (HR 1.14, P< .01) and number of prior recurrences (HR 1.24, P< .01) were associated with multiple recurrences; whereas maintenance BCG (HR 0.66, P = .03) was associated with reduced recurrences. The 5-year risk of progression varied significantly (P< .01) by number of recurrences: 9.5%, 21.9%, and 37.9% for patients with 1, 2, and 3+ recurrences, respectively. CONCLUSIONS: Multiple recurrences are common in IR-NMIBC and are associated with progression. Female sex, larger tumors, number of prior recurrences, and lack of maintenance BCG were associated with multiple recurrences. Multiple recurrences may prove useful as a clinical trial endpoint for IR-NMIBC.
引用
- Sharma V, Chamie K, Schoenberg M, et al. Natural History of Multiple Recurrences in Intermediate-Risk Non-Muscle Invasive Bladder Cancer: Lessons From a Prospective Cohort. Urology. 2022. PMID: 36574911. doi:10.1016/j.urology.2022.12.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。